Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

A Safety Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment

Multiple Cancer Types

This is a three-part study of NUC-3373 administered by intravenous (IV) infusion across two administration schedules, in separate combinations with leucovorin (LV), oxaliplatin, oxaliplatin and VEGF pathway inhibitors, oxaliplatin and EGFR inbibitors, irinotecan, irinotecan and VEGF pathway inhibitors, and irinotecan and EGFR inhibitors. The primary objective is to identify a recommended dose for NUC-3373 when combined with these agents.
Colon, Phase I, Rectal
Ciombor, Kristen

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: